MORRISVILLE, N.C., March 21, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) third quarter ended January 31, 2011. Highlights (activity through March 18, 2011)
- Received $2.07 million two-year grant from the U.S. Army to study the use of the company's Oxycyte ® perfluorocarbon (PFC) emulsion for traumatic brain injury.
- Signed research contract with Hackensack University Medical Center to study the wound healing properties of the company's Wundecyte™ gel. These studies are funded by the U.S. Department of Defense.
- Signed agreement to sell DERMACYTE ® skin care products to Swiss company that will target the Swiss, European Union and Russian markets. Company ordered additional 10,000 units in March.
- Signed agreement to sell DERMACYTE skin care products to Mexican company that will target the Mexican market.
- Signed a Letter of Intent with Sarasota Medical Products to pursue joint research and development in chronic ischemic wound care.
Third Quarter ResultsOxygen Biotherapeutics reported net revenue of $26,589 for the third quarter of fiscal 2011, compared to $12,165 for the comparable quarter the previous year due primarily to sales of DERMACYTE products to DSL. Gross margin was 51% as compared to 40% for the three months ended January 31, 2011 and 2010 respectively. Net revenue for the nine months ended January 31, 2011 was $58,825 compared to net revenue of $18,726 for the same period in fiscal year 2010. This was primarily due to the addition of two new DERMACYTE products and direct-to-consumer sales. Gross margin as a percent of revenue was 62% compared with 50% for the comparable nine-month period year over year. For the third-quarter ended January 31, 2011, we reported a net loss of approximately $2,544,187, or $0.11 per share, compared to a net loss of approximately $2,753,712, or $0.13 per share for the same period in the prior year. We reported a net loss of approximately $7,598,423, or $0.33 per share for the nine month period ended January 31, 2011, compared to a net loss of $7,739,602, or $0.41 per share for the same period in fiscal year 2010. Total operating expenses for the quarter ended January 31, 2011 were $2,781,344 compared to $2,764,776 for the same period in 2010. For the nine-month period ended January 31, 2011 the company had total operating expenses of $7,893,518 compared to $7,648,362 for the same period last year. The increase in operating expenses for the three-months ended January 31, 2011 was due to increases of approximately $200,000 and $325,000 in sales and marketing costs and general and administrative costs, respectively, partially offset by a decrease in research and development costs of approximately $510,000. The increase in operating expenses for the nine-months ended January 31, 2011 was due to increases of approximately $415,000 and $47,000 in sales and marketing costs and research and development costs, respectively, partially offset by a decrease in general and administrative costs of approximately $215,000.
The increases in marketing and sales expenses for the three- and nine-months ended January 31, 2011 were driven primarily by an increase in the costs incurred for compensation and direct advertising.The increase in general and administrative expenses for the three months ended January 31, 2011 was driven primarily by a reduction in costs incurred for banking and investor relations, travel related costs, compensation and consulting fees, offset by accruals for contingent liabilities associated with potential 409A tax liabilities. The decrease in general and administrative expenses for the nine months ended January 31, 2011 was driven primarily by a reduction in costs incurred for stock-based compensation and consulting fees; partially offset by an increase in depreciation and amortization, rent, compensation and accruals for contingent liabilities associated with potential 409A tax liabilities. The decrease in research and development expenses for the three-months ended January 31, 2011 was driven primarily by a reduction in the costs incurred for the development of Oxycyte and DERMACYTE, consulting costs, and preclinical study costs partially offset by an increase in costs incurred in connection with the Phase II-b clinical trials and compensation. The slight increase in research and development expenses for the nine-months ended January 31, 2011 was driven primarily by costs incurred for compensation and the costs associated with the Phase II-b clinical trials for Oxycyte, offset by a reduction in the costs incurred for the development of Oxycyte and DERMACYTE, consulting costs, and preclinical research costs. During the nine-month period ending January 31, 2011, as compared to the same period in 2010, total other income increased approximately $240,000 primarily due to an award of $244,489 under the Patient Protection and Affordable Care Act of 2010 received in November 2010. For the nine-month period ended January 31, 2011, the Company had cash and cash equivalents totaling $522,340, down from $632,706 at April 30, 2010.
Conference CallManagement will host a conference call on Tuesday, March 22, 2011 at 11 a.m. EDT. To access the live teleconference, dial (866) 578-5784 (U.S. and Canada) or (617) 213-8056 (international.) The participant pass code is 93886225. A live webcast will be available on our web site http://www.oxybiomed.com/investors.htm . A replay of the webcast will be available on the Oxygen Biotherapeutics website or by phone for a limited time. To access the replay by phone, call (888) 286-8010 (U.S. and Canada) or (617) 801-6888 (international) for a limited time. The pass code for the replay is 38473378. About Oxygen Biotherapeutics, Inc. Headquartered in Morrisvile, NC, Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is being formulated for both intravenous and topical delivery. Potential indications include traumatic brain injury, decompression sickness, wounds and dermatologic indications. This year, the company launched its DERMACYTE ® line of oxygen-rich skin care products. More information is available at www.oxybiomed.com or www.dermacyteUS.com . The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277 Financial Tables Follow The accompanying notes found in the Company's Form 10-Q filed with the SEC on March 21, 2011 are an integral part of these Financial Statements.
|OXYGEN BIOTHERAPEUTICS, INC.|
|(a development stage enterprise)|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|January 31, 2011 (Unaudited)||April 30, 2010|
|Cash and cash equivalents||$ 522,340||$ 632,706|
|Other current assets||36,607||695,195|
|Total current assets||1,316,254||2,184,826|
|Property and equipment, net||439,627||383,959|
|Intangible assets, net||967,612||907,710|
|Total assets||$ 2,853,233||$ 3,529,146|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable||$ 724,114||$ 499,044|
|Total current liabilities||1,704,697||1,399,341|
|Long-term notes payable, net||2,041,694||--|
|Long-term portion of convertible debt, net||--||2,767|
|Preferred stock, undesignated, authorized 10,000,000 shares; none issued or outstanding||--||--|
|Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 23,386,460 and 21,457,265, respectively||2,339||2,146|
|Stock subscription receivable||--||500,000|
|Additional paid-in capital||88,170,504||83,092,470|
|Deficit accumulated during the development stage||(89,066,001)||(81,467,578)|
|Total stockholders' equity||(893,158)||2,127,038|
|Total liabilities and stockholders' equity||$ 2,853,233||$ 3,529,146|
|OXYGEN BIOTHERAPEUTICS, INC.|
|(a development stage enterprise)|
|STATEMENT OF OPERATIONS|
|Three months ended January 31,||Nine months ended January 31,|
|Revenue||$ 52,562||$ 30,768||$ 95,543||$ 37,329|
|Cost of sales||25,973||18,603||36,718||18,603|
|Selling, general, and administrative||2,282,823||1,753,715||5,677,105||5,478,927|
|Research and development||498,521||1,011,061||2,216,413||2,169,435|
|Loss on impairment of long-lived assets||--||--||--||--|
|Total operating expenses||2,781,344||2,764,776||7,893,518||7,648,362|
|Net operating loss||2,754,755||2,752,611||7,834,693||7,629,636|
|Loss on extinguishment of debt||--||--||--||--|
|Net loss||$ 2,544,187||$ 2,753,712||$ 7,598,423||$ 7,739,602|
|Net loss per share, basic and diluted||$ (0.11)||$ (0.13)||$ (0.33)||$ (0.41)|
|Weighted average number of common shares outstanding, basic and diluted||23,391,155||20,614,082||23,331,614||18,845,881|
CONTACT: Ellen Corliss Vice President Corporate Communications & Investor Relations (919) 855-2112